Discover
ALLO
Allogene Therapeutics, Inc.
2.11
2 x 1.55
2 x 2.63
bid
ask
+
0.03
1.44%
2 @ 05:58 AM
2.13 +0.02 (0.95%)
| Ytd | 54.01% | |
| 1y | 78.81% |
2.05
day range
2.18
0.98
52 week range
4.46
| Open | 2.05 | Prev Close | 2.08 | Low | 2.05 | High | 2.18 | Mkt Cap | 728.28M |
| Vol | 12.87M | Avg Vol | 11.25M | EPS | -0.77 | P/E | N/A | Forward P/E | -1.50 |
| Beta | 0.84 | Short Ratio | 11.46 | Inst. Own | 80.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.10 | 200-d Avg | 1.80 | 1yr Est | 9.04 |
| Income Statement | |||
| Operating Expenses | 46.09M | ||
| Research and Development Expense | 32.00M | ||
| Selling, General and Administrative Expense | 14.09M | ||
| Operating Income | -46.09M | ||
| Interest Expense | 300.00K | ||
| Net Income | -42.61M | ||
| Net Income Common Stock | -42.61M | ||
| Net Income Common Stock (USD) | -42.61M | ||
| Consolidated Income | -42.61M | ||
| Earnings per Basic Share | -0.18 | ||
| Earnings per Basic Share (USD) | -0.18 | ||
| Earnings per Diluted Share | -0.18 | ||
| Earning Before Interest & Taxes (EBIT) | -42.31M | ||
| Earning Before Interest & Taxes (USD) | -42.31M | ||
| Weighted Average Shares | 240.29M | ||
| Weighted Average Shares Diluted | 240.29M | ||
| Balance Sheet | |||
| Cash and Equivalents | 40.60M | ||
| Cash and Equivalents (USD) | 40.60M | ||
| Investments | 236.58M | ||
| Investments Current | 236.58M | ||
| Current Assets | 273.29M | ||
| Property, Plant & Equipment Net | 108.84M | ||
| Total Assets | 395.96M | ||
| Current Liabilities | 28.33M | ||
| Total Liabilities | 117.08M | ||
| Accumulated Retained Earnings (Deficit) | -2.05B | ||
| Accumulated Other Comprehensive Income | -183.00K | ||
| Shareholders Equity | 278.88M | ||
| Shareholders Equity (USD) | 278.88M | ||
| Assets Non-Current | 122.67M | ||
| Liabilities Non-Current | 88.75M | ||
| Trade and Non-Trade Payables | 4.93M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.87M | ||
| Net Cash Flow from Financing | 21.12M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -21.38M | ||
| Capital Expenditure | -9.00K | ||
| Issuance (Purchase) of Equity Shares | 21.12M | ||
| Net Cash Flow from Investing | -29.59M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -29.58M | ||
| Net Cash Flow from Operations | -12.91M | ||
| Share Based Compensation | 8.27M | ||